Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biotechnology company focused on NK cell therapies for autoimmune diseases and cancers, Artiva uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and risk factors.
Recent Form 8-K filings highlighted in the available data include current reports on quarterly financial results, initial safety and translational data for AlloNK (AB-101) in autoimmune disease, and corporate matters such as amendments to the 2024 Equity Incentive Plan and equity award exchanges for certain executives. Other 8-Ks reference FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis and summarize clinical findings from ongoing Phase 1 and 2 trials combining AlloNK with anti-CD20 monoclonal antibodies after cyclophosphamide and fludarabine conditioning.
Through this page, users can review Artiva’s periodic reports, including 10-Q and 10-K filings, to understand research and development expenses, cash, cash equivalents and investments, net losses, and other financial information the company reports. AI-generated summaries can highlight key sections related to AlloNK’s clinical development, the CAR-NK oncology pipeline, the strategic partnership with GC Cell for NK cell manufacturing technology, and the company’s stated risk factors.
Investors can also reference proxy materials and equity plan amendments to see how Artiva structures compensation and equity incentives, as illustrated by the amendment to the 2024 Equity Incentive Plan approved at the 2025 Annual Meeting. Form 4 insider transaction reports, when available, can be used to monitor equity activity by directors and officers. Real-time updates from EDGAR combined with AI explanations help make ARTV’s regulatory record more accessible to readers who want to understand the company’s clinical, financial and governance disclosures in detail.
Artiva Biotherapeutics COO and CLO Jennifer Bush reported equity compensation and related tax withholding transactions in company stock. She received a grant of 117,300 shares of common stock as a restricted stock unit award under Artiva’s 2024 Equity Incentive Plan. On the same date, 3,515 shares were withheld by Artiva at a price of $4.00 per share to cover income tax obligations tied to vesting of restricted stock units, rather than sold in the open market. After these transactions, she directly owned 346,710 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. reported that its Chief Medical Officer, Subhashis Banerjee, acquired 102,000 shares of common stock through a grant described as a restricted stock unit award under the company’s 2024 Equity Incentive Plan. Following this equity award, his directly held common stock ownership increased to 152,000 shares.
Artiva Biotherapeutics reported insider equity activity by President and CEO Fred Aslan. He acquired 366,850 shares of common stock through a restricted stock unit award granted under the company’s 2024 Equity Incentive Plan, and 14,600 shares were withheld at $4.00 per share to cover income tax obligations from vesting. Following these transactions, he directly owned 1,562,198 common shares.
Artiva Biotherapeutics, Inc. reported an insider stock sale by its president and CEO, who also serves as a director. On December 15, 2025, the insider sold 3,187 shares of common stock at $6 per share.
Following this transaction, the insider directly owned 1,209,948 shares of Artiva Biotherapeutics common stock. The filing notes that the sale occurred under a Rule 10b5-1 trading plan adopted by the reporting person on July 23, 2024.
Artiva Biotherapeutics, Inc. reported an insider equity transaction for its SVP, Research and Development. On December 12, 2025, the officer received 67,253 restricted stock units (RSUs) of common stock at a price of $0, bringing their directly held common shares to 106,844.
On the same date, the company cancelled several employee stock options held by the officer pursuant to an option exchange, with exercise prices ranging from $5.01 to $13.47, leaving 0 derivative securities beneficially owned. The cancelled options had been scheduled to vest over multi-year periods based on continued service.
Artiva Biotherapeutics granted its Chief Tech Operations Officer 107,156 restricted stock units (RSUs) of common stock on December 12, 2025 under its 2024 Equity Incentive Plan as part of an option exchange.
On the same date, the company cancelled employee stock options covering 77,519 and 9,119 shares at an exercise price of $5.01 and options for 20,519 shares at $13.47, in exchange for the new RSUs. After these transactions, the officer directly beneficially owns 185,339 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. reported that a senior officer (COO, CLO, Secretary and Compliance Officer) exchanged stock options for restricted stock units on December 12, 2025.
The officer received 84,877 restricted stock units granted under the company’s 2024 Equity Incentive Plan at a stated price of $0, bringing direct beneficial ownership to 232,925 shares of common stock.
As part of the same option exchange, the company cancelled employee stock options to buy 41,039, 9,119, 14,202 and 20,519 shares of common stock with exercise prices ranging from $5.01 to $13.47, all of which now show zero derivative securities beneficially owned.
Artiva Biotherapeutics, Inc. President and CEO, who also serves as a director, reported an equity compensation change effective December 12, 2025. The company cancelled several employee stock options listed in the filing, with exercise prices ranging from $5.01 to $13.47 per share, covering multiple grants that were scheduled to vest over multi-year periods.
In exchange for the cancelled options, the reporting person received 869,136 restricted stock units under the company’s 2024 Equity Incentive Plan, recorded at a price of $0 per unit. Following this option-for-RSU exchange, the reporting person beneficially owned 1,213,135 shares of the company’s common stock, held directly.
Artiva Biotherapeutics, Inc. implemented a one-time exchange program allowing a limited group of employees, including its President and CEO Fred Aslan and COO/CLO Jennifer Bush, to surrender underwater stock options for restricted stock units (RSUs) under the 2024 Equity Incentive Plan. The goal is to enhance retention and better align employee incentives with stockholders by replacing options with little current value.
Dr. Aslan surrendered options to purchase 869,136 shares of common stock and Ms. Bush surrendered options to purchase 84,877 shares. In return, they received RSUs equal to their surrendered vested and unvested options. For the RSUs issued in exchange for vested options, 50% will vest on August 15, 2026, and 25% will vest on each of November 15, 2026, and February 15, 2027, with full acceleration if they are terminated other than for Cause or resign for Good Reason. RSUs issued for unvested options will vest between August 15, 2026, and February 15, 2029, with an additional six months of vesting acceleration upon those same termination events.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its Senior Vice President of Research and Development on a Form 4. On 11/15/2025, 1,375 shares of common stock were surrendered at a price of $3.25 per share, coded as an “F” transaction, which indicates shares withheld to cover taxes related to the vesting of restricted stock units. After this tax withholding event, the reporting person beneficially owned 39,591 shares of Artiva common stock directly. This was a routine administrative transaction tied to equity compensation rather than an open-market sale.